GLP-1 & compounded medication availability in Connecticut (2026)
Connecticut is the rare state where the loudest regulator is not the pharmacy authority but the Attorney General, whose office has spent 2025 and 2026 sending warning letters, cease-and-desist demands and settlement papers to med spas and online sellers marketing compounded GLP-1 drugs as if they were FDA-approved. That enforcement campaign is aimed at deceptive marketing, not at patient-specific telehealth prescribing, and the distinction decides every row in the table below. Here is what actually ships to Connecticut addresses, and the cited record of what the state’s enforcers have done.
What ships to Connecticut: all ten lines
| Product line | Available in Connecticut? | Typical delivery | Notes |
|---|---|---|---|
| GLP-1 (compounded semaglutide) | Yes | 8–10 business days | Dispensed on patient-specific prescriptions after an individual provider evaluation. See the enforcement context in the regulator section. |
| GLP-1/GIP (compounded tirzepatide) | Yes | 8–10 business days | Same patient-specific basis as the GLP-1 row; same enforcement context applies. |
| NAD+ | Yes | 8–10 business days | Ships from licensed partner pharmacies registered for Connecticut. |
| Sermorelin | Yes | 8–10 business days | Longevity family; identical ordering flow to every other state. |
| Glutathione | No | N/A | Not in the OrderlyMeds formulary today. |
| BPC-157 | Yes | 8–10 business days | Compounded injectable; its federal record is set out below. |
| TB-500 | Yes | 8–10 business days | Compounded injectable. Read its own section before ordering. |
| KPV | No | N/A | Not carried in any state; our peptide lines are injectables only. |
| Epitalon | Yes | 8–10 business days | Compounded injectable; federal standing below. |
| MOTS-c | Yes | 8–10 business days | Compounded injectable; its federal record is its own, below. |
A “No” is a fact we publish, not a gap we hide. Connecticut rows on this page were last reviewed on November 16, 2026.
Research peptides in Connecticut: BPC-157, TB-500, KPV, Epitalon & MOTS-c
Four of these five peptides are in the OrderlyMeds formulary for Connecticut: BPC-157, TB-500, Epitalon and MOTS-c, each compounded as an injectable and dispensed on a patient-specific prescription. KPV is the exception, in Connecticut and everywhere else, because we compound these lines as injectables only. Connecticut’s enforcement activity has centered on GLP-1 marketing claims rather than on these peptides, but each section below states its line’s own federal record regardless, because that record, not marketing, is what a buyer needs.
BPC-157 in Connecticut
OrderlyMeds fills BPC-157 for Connecticut addresses as a compounded injectable, on a patient-specific prescription written after an individual provider evaluation. The two federal facts below apply in full.
FDA’s evaluation of bulk drug substances for compounding under section 503A placed BPC-157 in Category 2, and BPC-157 has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense BPC-157 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
TB-500 in Connecticut
TB-500 ships to Connecticut as a compounded injectable under a patient-specific prescription. Its federal record follows.
FDA’s evaluation of bulk drug substances for compounding under section 503A placed TB-500 (thymosin beta-4 fragment) in Category 2, and TB-500 (thymosin beta-4 fragment) has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense TB-500 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
KPV in Connecticut
We do not ship KPV to Connecticut, or anywhere. Our peptide lines are compounded as injectables, and KPV is not carried in that form.
FDA’s evaluation of bulk drug substances for compounding under section 503A placed KPV in Category 2, and KPV has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense KPV pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
Epitalon in Connecticut
Epitalon is in the Connecticut catalog as a compounded injectable, dispensed on a patient-specific prescription. Its federal standing is set out below.
FDA’s evaluation of bulk drug substances for compounding under section 503A placed Epitalon in Category 2, and Epitalon has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense Epitalon pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
MOTS-c in Connecticut
MOTS-c reaches Connecticut addresses as a compounded injectable on a patient-specific prescription. Its federal record differs from the four lines above and is stated on its own terms below.
FDA has evaluated MOTS-c as a bulk drug substance nominated for the section 503A bulks list and proposed that neither MOTS-c (free base) nor MOTS-c acetate be included on it, and MOTS-c has no FDA-approved indication. MOTS-c was formerly listed in Category 2 of FDA’s interim compounding policy, and it is no longer on that active list as of FDA’s April 22, 2026 update, because the nomination was withdrawn by the nominator. FDA’s record for the substance notes a potential immunogenicity concern by certain routes and no clinical data in humans, and FDA presented MOTS-c to its Pharmacy Compounding Advisory Committee in July 2026. Under the enforcement-discretion policy HHS published October 30, 2026 at 91 FR 68526, HHS does not intend to act against a state-licensed pharmacy, Federal facility, or licensed physician compounding MOTS-c under section 503A, limited to subcutaneous or intramuscular administration, under a valid patient-specific prescription, and subject to the policy’s other conditions, while rulemaking on the bulks list is pending. That policy does not add MOTS-c to the bulks list and does not make it an FDA-approved drug. Sources: FDA — bulk drug substances that may present significant safety risks (Category 2 and withdrawn nominations) · FDA — PCAC briefing document, July 23–24, 2026 (MOTS-c proposals, points 7–8) · HHS — 91 FR 68526, enforcement-discretion policy for 503A peptide compounding.
What Connecticut’s regulators and Attorney General say about compounded medications
Pharmacy oversight in Connecticut runs through the Department of Consumer Protection, and since mid-2025 the state’s most visible activity on compounded medications has come from the Attorney General’s office. Every action in that campaign has targeted sellers marketing compounded GLP-1s deceptively: as FDA-approved, as generics, or to the general population without individual prescriptions. None of it changes the baseline licensure path a telehealth prescription follows.
Pharmacy practice in Connecticut — including licensure of pharmacies, pharmacists and out-of-state pharmacies shipping into the state — is overseen by the Commission of Pharmacy within the Department of Consumer Protection. Source: Connecticut Department of Consumer Protection — Commission of Pharmacy.
Connecticut’s Attorney General has pursued active enforcement on compounded GLP-1 marketing: warning letters to weight-loss clinics and med spas in May 2025, cease-and-desist letters to three sellers in December 2025, and a lawsuit plus settlements under the Connecticut Unfair Trade Practices Act. Source: Office of the Attorney General, December 3, 2025.
The Attorney General’s stated position is that compounded semaglutide and tirzepatide may no longer be prescribed to the general patient population following the FDA shortage resolutions, and that advertising them as FDA-approved or as generics is deceptive; settlements announced May 6, 2026 imposed six-figure penalties (largely suspended) and monitoring obligations on two online platforms. Source: Office of the Attorney General, May 6, 2026.
Connecticut permits prescribing on the basis of a telehealth encounter that meets the state’s standard of care. Source: Center for Connected Health Policy (CCHP) Policy Finder.
In practice, a Connecticut order works the way the Attorney General’s own enforcement record implies it should: an individual evaluation by a Connecticut-licensed provider, a patient-specific prescription, and fulfillment by a pharmacy registered for Connecticut, with no claim, here or anywhere, that a compounded medication is FDA-approved. Pricing is national; the figure on our pricing page is the Connecticut figure.
Connecticut availability FAQs
Is compounded semaglutide available in Connecticut?
Yes, on a patient-specific prescription issued after an individual evaluation by a Connecticut-licensed provider. That patient-specific basis is exactly the line Connecticut’s Attorney General has drawn in its enforcement against sellers marketing compounded GLP-1s to the general population. New customers start at $74/month for the first two months.
Does Connecticut’s GLP-1 enforcement affect my telehealth order?
The enforcement campaign documented above targets deceptive marketing: sellers claiming compounded drugs are FDA-approved or generic, or selling without valid prescriptions. An order placed through an individual provider evaluation and filled on a patient-specific prescription is a different path, and it is the only path OrderlyMeds uses.
Can I get BPC-157 or other research peptides shipped to Connecticut?
Four of the five: BPC-157, TB-500, Epitalon and MOTS-c ship to Connecticut as compounded injectables under patient-specific prescriptions. KPV does not, because we compound these lines as injectables only. Each line’s section above states its own federal record, which applies no matter where you buy.
How long does delivery to Connecticut take?
Our published window is 8–10 business days from signup, from licensed partner pharmacies registered to ship into Connecticut.
Keep exploring
Ready when you are
See if you’re eligible
Compounded semaglutide from $74/month for your first 2 months — provider visit, medication, syringes, and shipping all included, at the same price for every dose. No membership fees.
Check eligibilitySecure. Private. No commitment
